The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

17 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Rigidified A3 Adenosine Receptor Agonists: 1-Deazaadenine Modification Maintains High in Vivo Efficacy.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.EBI
National Institute of Diabetes and Digestive and Kidney Diseases
Interaction of AEBI
National Cancer Institute (Ba, Mm, Sl, Sva)
AEBI
National Institute of Diabetes and Digestive and Kidney Disease
Selective AEBI
National Institute of Diabetes and Digestive and Kidney Diseases
Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as AEBI
National Institute of Diabetes and Digestive and Kidney Disease
Novel non-xanthine antagonist of the AEBI
Bayer Pharmaceuticals
Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human AEBI
Medical College of Wisconsin
Design and in Vivo Characterization of AEBI
Medical College of Wisconsin
AEBI
Rheinische Friedrich-Wilhelms-Universitat Bonn
Structure-Based Design, Synthesis by Click Chemistry and EBI
National Institute of Diabetes and Digestive and Kidney Diseases